不同剂量替罗非班联合替格瑞洛对NSTEMI患者短期心血管事件及血小板聚集率的影响 |
| |
引用本文: | 陆胜,余再新,黄友良,谭碧峰.不同剂量替罗非班联合替格瑞洛对NSTEMI患者短期心血管事件及血小板聚集率的影响[J].心脏杂志,2017,29(4):427-430. |
| |
作者姓名: | 陆胜 余再新 黄友良 谭碧峰 |
| |
作者单位: | 中南大学湘雅医院心内科, 湖南 长沙 418000 |
| |
摘 要: | 目的 探讨不同剂量替罗非班联合替格瑞洛对急性非ST段抬高型心肌梗死(NSTEMI)患者短期心血管事件及血小板聚集率的影响。 方法 收集128例NSTEMI患者,根据不同用药方式分为替格瑞洛组(A组,n=39)、常规剂量替罗非班联合替格瑞洛组(B组,n=46)和小剂量替罗非班联合替格瑞洛组(C组,n=41)。治疗4周后,比较3组患者的血小板聚集率、血纤维蛋白原(Fib)水平以及心血管事件、不良反应发生率。 结果 治疗4周后,A组复合项终点事件发生率明显高于B组和C组,差异有统计学意义(P<0.05);治疗1、4周后,B组和C组血小板聚集率、血Fib水平均显著低于A组,差异有统计学意义(P<0.05),B组和C组血小板聚集率、血Fib水平比较差异均无统计学意义 ;B组不良反应发生率明显高于A组和C组,差异有统计学意义(P<0.05)。 结论 常规剂量和小剂量替罗非班联合替格瑞洛均可减少NSTEMI患者短期心血管事件的发生,增强血小板聚集的抑制作用,且小剂量的替罗非班减少了不良反应的发生。
|
关 键 词: | 心肌梗死 非ST段抬高型,急性 替罗非班 替格瑞洛 血小板聚集 心血管事件 |
收稿时间: | 2016-09-18 |
Effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with non-ST-elevation myocardial infarction |
| |
Institution: | Department of Cardiology, Xiangya Hospital, Central South University, Changsha 418000, Hunan, China |
| |
Abstract: | AIM To investigate the effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with (NSTEMI). METHODS One hundred and twenty-eight NSTEMI patients in our hospital were included in the study. According to different treatment methods, the patients were divided into ticagrelor group (group A, n=39), the conventional dose of tirofiban combined with ticagrelor group (group B, n=46) and small dose of tirofiban combined with Grillo group (group C, n=41). After 4 weeks of treatment, the platelet aggregation rate, fibrinogen (Fib) level and cardiovascular events, and incidence of adverse events were compared between the three groups. RESULTS After 4 weeks of treatment, the occurrence rate of composite endpoint in group A was significantly higher than those in group B and group C (P<0.05). The platelet aggregation rate and blood Fib levels in group B and group C were significantly lower than those in group A (P<0.05). The incidence of adverse reactions in group B was significantly higher than those in group A and group C (P<0.05). CONCLUSION Conventional dose and small dose of tirofiban combined with ticagrelor can reduce short-term cardiovascular events in NSTEMI patients and enhance the inhibition of platelet aggregation. Small dose of tirofiban reduces the incidence of adverse reactions. |
| |
Keywords: | |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《心脏杂志》浏览原始摘要信息 |
| 点击此处可从《心脏杂志》下载免费的PDF全文 |
|